Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double

KEY TAKEAWAYSNovo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition."The Danish firm is projecting 2025 sales growth of 16% to 24% at constant exchange rates, below the 26% growth it produced in 2024.Novo Nordisk said it plans to file for the first regulatory approval for its weight-loss drug CagriSema during the first quarter of 2026. Novo Nor ...